Pitfalls in new artemisinin-containing antimalarial drug development

Trends in Parasitology

Volumn 27, Issue 2, 2011, Pages 82-90

  Jambou, Ronan ^a   Le Bras, Jacques ^b   Randrianarivelojosia, Milijaona ^c  

^a INSTITUT PASTEUR   (France)

^b BICHAT HOSPITAL   (France)

^c INSTITUT PASTEUR DE MADAGASCAR   (Madagascar)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; BENFLUMETOL; MEFLOQUINE; PYRIMETHAMINE; SULFADOXINE;

BIOEQUIVALENCE; CROP PRODUCTION; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MARKETING; DRUG QUALITY; DRUG USE; HUMAN; NONHUMAN; PLASMODIUM FALCIPARUM; REVIEW;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MALARIA;

ARTEMISIA;

EID: 79251598326     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2010.09.004     Document Type: Review

References (81)

1. WHO (2008) World Malaria Report, WHO/HTM/GMP/2008.1, World Health Organization.
2. White N.J. Qinghaosu (artemisinin): the price of success. Science 2008, 320:330-334.
3. Carrara V.I., et al. Deployment of early diagnosis and mefloquine- artesunate treatment of falciparum malaria in Thailand: the Task Malaria Initiative. PLoS Med. 2006, 3:e183.
4. Bhattarai A., Kachur S.P. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med. 2007, 4:e309.
5. WHO (2001) Antimalarial Drug Combination Therapy: Report of a Technical Consultation, WHO/CDS/RBM/2001.35, World Health Organization.
6. China-Africa Cooperation (2008) Report of the 3rd Summit of China-Africa Cooperation, Forum on China-Africa Cooperation.
7. Nyunt M.M., Plowe C.V. Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance. Clin. Pharmacol. Ther. 2007, 82:601-605.
8. Haynes R.K. From artemisinin to new artemisinin antimalarials: biosynthesis, extraction, old and new derivatives, stereochemistry and medicinal chemistry requirements. Curr. Top. Med. Chem. 2006, 6:509-537.
9. Food and Drug Administration Guidance for Industry - Bioavailability and Bioequivalence Studies for Orally Administered Drug Products; General Considerations (CDER) 2002, US Center for Drug Evaluation and Research.
10. Huang L., et al. Mapping the potential distribution of high artemisinin-yielding Artemisia annua L. (Qinghao) in China with a geographic information system. Chin. Med. 2010, 17:18.
11. Olsson M.E., et al. Localization of enzymes of artemisinin biosynthesis to the apical cells of glandular secretory trichomes of Artemisia annua L. Phytochemistry 2009, 70:1123-1128.
12. Arsenault P.R., et al. Effect of sugars on artemisinin production in Artemisia annua L.: transcription and metabolite measurements. Molecules 2010, 15:2302-20218.
13. Wang J.W., et al. Stimulation of artemisinin synthesis by combined cerebroside and nitric oxide elicitation in Artemisia annua hairy roots. Appl. Microbiol. Biotechnol. 2009, 85:285-292.
14. Davies M.J., et al. Enhancement of artemisinin concentration and yield in response to optimization of nitrogen and potassium supply to Artemisia annua. Ann. Bot. 2009, 104:315-323.
15. Jain R., Dixit V.K. Effect of miconazole and terbinafine on artemisinin content of shooty teratoma of Artemisia annua. Nat. Prod. Commun. 2010, 5:185-190.
16. Ferreira J.F., Luthria D.L. Drying affects artemisinin, dihydroartemisinic acid, artemisinic acid, and the antioxidant capacity of Artemisia annua L. leaves. J. Agric. Food Chem. 2010, 58:1691-1698.
17. Khangholil S., Rezaeinodehi A. Effect of drying temperature on essential oil content and composition of sweet wormwood (Artemisia annua) growing wild in Iran. Pak. J. Biol. Sci. 2008, 11:934-937.
18. Delabays N., et al. The genetics of artemisinin content in Artemisia annua L. and the breeding of high yielding cultivars. Curr. Med. Chem. 2001, 8:1795-1801.
19. Paul S., et al. Enhancement of artemisinin content through four cycles of recurrent selection with relation to heritability, correlation and molecular marker in Artemisia annua L. Planta Med. 2010, 76:1468-1472.
20. Graham I.A., et al. The genetic map of Artemisia annua L. identifies loci affecting yield of the antimalarial drug artemisinin. Science 2010, 327:328-331.
21. Arsenault P.R., et al. Recent advances in artemisinin production through heterologous expression. Curr. Med. Chem. 2008, 15:2886-2896.
22. Rydén A.M., et al. The molecular cloning of dihydroartemisinic aldehyde reductase and its implication in artemisinin biosynthesis in Artemisia annua. Planta Med. 2010, May 19.
23. Zeng Q., et al. Production of artemisinin by genetically-modified microbes. Biotechnol. Lett. 2008, 30:581-592.
24. Nosten F. Artemisinin: large community studies Trans. R. Soc. Trop. Med. Hyg. 1994, 88:S45-46.
25. Jiang J.B., et al. Antimalarial activity of mefloquine and qinghaosu. Lancet 1982, 2:285-288.
26. Shah V.P., et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur. J. Drug. Metab. Pharmacokinet. 1991, 16:249-255.
27. Chen M.L., et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm. Res. 2001, 18:1645-1650.
28. Food and Drug Administration (2000) Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, US Center for Drug Evaluation and Research.
29. Food and Drug Administration (2000) Guidance for Industry - Bioavailability and Bioequivalence Studies for Orally Administered Drug Products; General Considerations, US Center for Drug Evaluation and Research.
30. Food and Drug Administration Guidance for Industry: Statistical Approaches to Establishing Bioequivalence 2001, US Center for Drug Evaluation and Research.
31. Food and Drug Administration Statistical Methods for Obtaining Confidence Intervals for Individual and Population Bioequivalence Criteria 2007, US Center for Drug Evaluation and Research.
32. Diletti E., et al. Sample size determination for bioequivalence assessment by means of confidence intervals. Int. J. Clin. Pharmacol. Ther. Toxicol. 1991, 29:1-8.
33. el-Tahtawy A.A., et al. Evaluation of bioequivalence of highly variable drugs using Monte Carlo simulations. I. Estimation of rate of absorption for single and multiple dose trials using Cmax. Pharm. Res. 1995, 12:1634-1641.
34. Westlake W.J. Use of confidence intervals in analysis of comparative bioavailability trials. J. Pharm. Sci. 1972, 61:1340-1341.
35. Schuirmann D.J. A comparison of the two one-sided test procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharm. Biopharm. 1987, 15:657-680.
36. Bi J. Similarity testing using paired comparison method. Food Qual. Prefer. 2007, 18:500-507.
37. Vaillant M., Olliaro P. Geometric least square means ratios for the analysis of Plasmodium falciparum in vitro susceptibility to antimalarial drugs. Malar. J. 2007, 6:1-11.
38. Atemnkeng M.A., et al. Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Trop. Med. Int. Health 2007, 12:68-74.
39. Krishna S., et al. Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends Mol. Med. 2006, 12:200-205.
40. Jambou R., et al. Resistance of Plasmodium falciparum field isolates to in vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005, 366:1960-1963.
41. Ibrahim M.L., et al. Polymorphism of PfATPase in Niger: detection of three new point mutations. Malar. J. 2009, 8:28.
42. Wongsrichanalai C., Meshnick S.R. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg. Infect. Dis. 2008, 14:716-719.
43. Lim P., et al. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar. J. 2009, 8:11.
44. Carrara V.I., et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 2009, 4:e4551.
45. Dondorp A.M., et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 2009, 361:455-467.
46. Vinayak S., et al. Multiple genetic backgrounds of the amplified Plasmodium falciparum multidrug resistance (pfmdr1) gene and selective sweep of 184F mutation in Cambodia. J. Infect. Dis. 2010, 201:1551-1560.
47. Dahlström S., et al. Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa. J. Infect. Dis. 2009, 200:1456-1464.
48. Witkowski B., et al. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by aquiescence mechanism. Antimicrob. Agents Chemother. 2010, 54:1872-1877.
49. Nawaz F., et al. Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda. J. Infect. Dis. 2009, 200:1650-16657.
50. Bonnet M., et al. Varying efficacy of artesunate + amodiaquine andartesunate + sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in vivo studies. Malar. J. 2009, 8:192.
51. Sykes A., et al. Azithromycin plus artesunate versus artemether-lumefantrine for treatment ofuncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin. Infect. Dis. 2009, 49:1195-1201.
52. Fanello C.I., et al. A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:412-420.
53. Sertel S., et al. Pharmacogenomic identification of c-Myc/Max-regulated genes associated withcytotoxicity of artesunate towards human colon, ovarian and lung cancer celllines. Molecules 2010, 15:2886-2910.
54. Michaelis M., et al. Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma celllines. Biochem. Pharmacol. 2010, 79:130-136.
55. Ilett K.F., et al. The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br. J. Clin. Pharmacol. 2002, 53:23-30.
56. Batty K.T., et al. A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. Br. J. Clin. Pharmacol. 1998, 45:123-129.
57. Alin M.H., et al. Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, mefloquine. Am. J. Trop. Med. Hyg. 1995, 53:639-645.
58. Batty K.T., et al. Chemical stability of artesunate injection and proposal for its administration by intravenous infusion. J. Pharm. Pharmacol. 1996, 48:22-26.
59. Li Q., et al. The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans. Am. J. Trop. Med. Hyg. 2006, 75:817-826.
60. Ittarat W., et al. Effects of alpha-thalassemia on pharmacokinetics of the antimalarial agent artesunate. Antimicrob. Agents Chemother. 1998, 42:2332-2335.
61. Newton P., et al. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob. Agents Chemother. 2000, 44:972-977.
62. Barnes K.I., et al. Efficacy of rectal artesunate compared with parenteral quinine in initial treatment of moderately severe malaria in African children and adults: a randomised study. Lancet 2004, 363:1598-1605.
63. Benakis A., et al. Pharmacokinetics/pharmacodynamics findings after repeated administration of aretsunate thermostable suppositories (rectocaps) in Vietnamese patients with uncomplicated malaria. Eur. J. Drug Metab. Pharmacokinet. 2006, 31:41-45.
64. Hien T.T., et al. Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob. Agents Chemother. 2004, 48:4234-4239.
65. Li Q., et al. Toxicokinetics and hydrolysis of artelinate and artesunate in malaria-infected rats. Int. J. Toxicol. 2005, 24:241-250.
66. Price R.N., et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob. Agents Chemother. 2007, 51:4090-4497.
67. Moore B.R., et al. Piperaquine pharmacodynamics and parasite viability in a murine malaria model. Antimicrob. Agents Chemother. 2009, 53:2707-2713.
68. Clark R.L., et al. Developmental toxicity of artesunate in the rat: comparison to other artemisinins, comparison of embryotoxicity and kinetics by oral and intravenous routes, and relationship to maternal reticulocyte count. Birth Defects Res. B. Dev. Reprod. Toxicol. 2008, 83:397-406.
69. Nontprasert A., et al. Assessment of the neurotoxicity of parenteral artemisinin derivatives in mice. Am. J. Trop. Med. Hyg. 1998, 59:519-522.
70. Davis T.M., et al. Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria. Antimicrob. Agents Chemother. 2003, 47:368-370.
71. Efferth T., Kaina B. Toxicity of the antimalaria artemisinin and its derivatives. Crit. Rev. Toxicol. 2010, 40:405-421.
72. Li Q., et al. Severe embryolethality of artesunate related to pharmacokinetics following intravenous and intramuscular doses in pregnant rats. Birth Defects Res. B Dev. Reprod. Toxicol. 2009, 86:385-393.
73. Ahmed T., et al. Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects. J. Clin. Pharmacol. 2008, 48:166-175.
74. Roshammar D., et al. Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur. J. Clin. Pharmacol. 2006, 62:335-341.
75. Liu C., et al. Pharmacokinetics of piperaquine after single and multiple oral administrations in healthy volunteers. Yakugaku Zasshi. 2007, 127:1709-1714.
76. Nguyen D.V., et al. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. Antimicrob. Agents Chemother. 2009, 53:3534-3537.
77. Ashley E.A., et al. Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 2010, 66:705-712.
78. D'alessandro U. Progress in the development of piperaquine combinations for the treatment of malaria. Curr. Opin. Infect. Dis. 2009, 22:588-592.
79. Sim I.K., et al. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob. Agents Chemother. 2005, 49:2407-2411.
80. Tarning J., et al. Pitfalls in estimating piperaquine elimination. Antimicrob. Agents Chemother. 2005, 49:5127-5128.
81. Tarning J., et al. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob. Agents Chemother. 2008, 52:1052-1061.